Literature DB >> 2565265

Pharmacological modulation of cutaneous reactivity to histamine: a double-blind acute comparative study between cetirizine, terfenadine and astemizole.

L Ghys1, J P Rihoux.   

Abstract

In a double-blind study performed in 81 healthy volunteers, 10 mg cetirizine and 60 mg terfenadine given orally in a single administration significantly inhibited skin reactivity to histamine. Astemizole (10 mg) was completely ineffective. The inhibitory effect of cetirizine was potent and regular whereas 6/28 (21%) volunteers did not respond to terfenadine. The difference observed between cetirizine and terfenadine might be due to differences in the metabolism of the two drugs after administration: terfenadine is rapidly and extensively metabolized whereas cetirizine is directly active without the need for biotransformation and, indeed is poorly metabolized.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565265     DOI: 10.1177/030006058901700103

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Counseling the elderly on decision making for the end of life. Practical issues for physicians.

Authors:  N Nazerali
Journal:  Can Fam Physician       Date:  1995-05       Impact factor: 3.275

Review 2.  Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  J P Rihoux; S Mariz
Journal:  Clin Rev Allergy       Date:  1993

Review 3.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.

Authors:  D M Campoli-Richards; M M Buckley; A Fitton
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 4.  Urticaria. Recognition, causes and treatment.

Authors:  A D Ormerod
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 5.  Tuberculosis in the 1990s. Issues for primary care physicians.

Authors:  J M Fitzgerald
Journal:  Can Fam Physician       Date:  1995-06       Impact factor: 3.275

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.